Stockscreener 앱 받기
452.04
1.37%
6.11
시장 영업 전:
453.09
1.05
+0.23%
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
National Bank of Canada FI Acquires 99,751 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Castleark Management LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
MASTERINVEST Kapitalanlage GmbH Purchases Shares of 5,784 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Westwood Holdings Group Inc. - MarketBeat
Lazard Asset Management LLC Has $213.83 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Provident Investment Management Inc. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Position Lifted by Liontrust Investment Partners LLP - MarketBeat
Marex Group plc Invests $2.98 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Coppell Advisory Solutions LLC Buys 2,846 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025? - Yahoo Finance
How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX is Bellevue Group AG's 8th Largest Position - MarketBeat
2 Healthcare Stocks to Buy Ahead of the New Year - The Globe and Mail
Investors heavily search Vertex Pharmaceuticals Incorporated (VRTX): Here is what you need to know - MSN
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Sei Investments Co. Has $132.41 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CIBC Asset Management Inc Sells 4,393 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - Finviz
Alliancebernstein L.P. Has $1.95 Billion Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025) - ts2.tech
United States Orphan Drugs Market to Reach USD 486.51 Billion - openPR.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $515.00 at Wells Fargo & Company - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Investment Management Corp of Ontario - MarketBeat
This Week’s CGT News: Vertex’s Gene Therapies Show Promise in Younger Children - The Medicine Maker
Wells Fargo Adjusts PT on Vertex Pharmaceuticals to $515 From $460, Maintains Overweight Rating - marketscreener.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Jump Financial LLC - MarketBeat
Ossiam Has $2.05 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Diadema Partners LP Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank of Nova Scotia Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
State Street Corp Has $5.24 Billion Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by SVB Wealth LLC - MarketBeat
Daiwa Securities Group Inc. Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Axa S.A. Buys 10,477 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
Disney, Nu Holdings, Phillips 66 And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
Vertex Will Seek Regulatory Approval for Casgevy in Younger Sickle Cell, Beta-Thalassemia Patients - Precision Medicine Online
Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Vertex's Gene Therapy Works In Children With Blood Disorders - Benzinga
Thematics Asset Management Acquires 2,642 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - BioSpace
Federated Hermes Inc. Acquires 23,726 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
David And Goliath: How A Parent-Led Buyers’ Club Challenged Cystic Fibrosis Giant Vertex - Citeline News & Insights
VRTX Stock Quote Price and Forecast - CNN
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
Marshall Wace LLP Has $52.09 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
California Public Employees Retirement System Has $322.79 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cerity Partners LLC Purchases 10,768 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Arrowstreet Capital Limited Partnership Purchases Shares of 61,470 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? - sharewise.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Chairman Jeffrey Leiden Sells 63,781 Shares - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Charles Wagner Jr Sells 14,000 Shares - MarketBeat
Press Release Service: Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - CRISPR Medicine News
Best Biotech Stocks To Watch NowDecember 6th - MarketBeat
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the - pharmiweb.com
Vertex presents new data on Casgevy at ASH - The Pharma Letter
Vertex Pharmaceuticals Incorporated Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - marketscreener.com
Vertex Presents New CASGEVY Data Highlighting Benefits In Children Ages 5-11 - Nasdaq
Vertex CRISPR therapy hits early goal in children with blood disorders - BioPharma Dive
Vertex's gene therapy shows promise in younger children with blood disorders - Reuters
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - Via TT
Mirabella Financial Services LLP Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Epoch Investment Partners Inc. Sells 20,810 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
First Trust Advisors LP Purchases 143,084 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Insider Sell: WAGNER CHARLES F JR Sells 14,000 Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharma executive chairman sells $28.6m in stock - Investing.com India
Vertex Pharmaceuticals Insider Sold Shares Worth $2,024,955, According to a Recent SEC Filing - marketscreener.com
VP Tatsis Sells 4,500 ($2M) Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
Vertex Pharmaceuticals EVP Sells Shares Under Trading Plan - TradingView
VRTX Analyst Rating Update: Morgan Stanley Raises Price Target | VRTX Stock News - GuruFocus
Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $564 From $516, Maintains Overweight Rating - marketscreener.com
0.74%
0.91%
자본화:
|
볼륨(24시간):